The safety of available treatment options for iron-deficiency anemia

References

• Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014;123:615–624.
   PubMed Web of Science ®Google Scholar
• Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372:1832–1843.
   PubMed Web of Science ®Google Scholar
• WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Geneva, Switzerland: Vitamin and Mineral Nutrition Information System, World Health Organization; 2011.
   Google Scholar
• Muñoz M, Gómez-Ramírez S, Campos A, et al. Pre-operative anaemia: prevalence, consequences and approaches to management. Blood Transfus. 2015;13:370–379.
   PubMed Web of Science ®Google Scholar
• Muñoz M, Acheson AG, Auerbach M, et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia. 2017;72:233–247.
   PubMed Web of Science ®Google Scholar
• Mast AE, Blinder MA, Gronowski AM, et al. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem. 1998;44:45–51.
   PubMed Web of Science ®Google Scholar
• Muñoz M, García-Erce JA, Remacha AF. Disorders of iron metabolism. Part II: iron deficiency and iron overload. J Clin Pathol. 2011;64:287–296.
   PubMed Web of Science ®Google Scholar
• Thomas DW, Hinchliffe RF, Briggs C, et al. British committee for standards in haematology. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol. 2013;161:639–648.
   PubMed Web of Science ®Google Scholar
• Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016;91:31–38.
   PubMed Web of Science ®Google Scholar
• Martin-Cabrera P, Hung M, Ortmann E, et al. Clinical use of low haemoglobin density, transferrin saturation, bone marrow morphology, Perl’s stain and other plasma markers in the identification of treatable anaemia presenting for cardiac surgery in a prospective cohort study. J Clin Pathol. 2015;68:923–930.
   PubMed Web of Science ®Google Scholar
• Schrier SL, Auerbach M Treatment of iron deficiency anemia in adults. UpToDate. 2017. cited 2017 Apr. Available from: https://www.uptodate.com/contents/treatment-of-iron-deficiency-anemia-in-adults
   Google Scholar
• Parker MJ. Iron supplementation for anemia after hip fracture surgery: a randomized trial of 300 patients. J Bone Joint Surg Am. 2010 Feb;92(2):265–269.
   PubMedGoogle Scholar
• Prasad N, Rajamani V, Hullin D, et al. Post-operative anaemia in femoral neck fracture patients: does it need treatment? A single blinded prospective randomised controlled trial. Injury. 2009 Oct;40(10):1073–1076.
   PubMed Web of Science ®Google Scholar
• Mundy GM, Birtwistle SJ, Power RA. The effect of iron supplementation on the level of haemoglobin after lower limb arthroplasty. J Bone Joint Surg Br. 2005 Feb;87(2):213–217.
   PubMedGoogle Scholar
• Weatherall M, Maling TJ. Oral iron therapy for anaemia after orthopaedic surgery: randomized clinical trial. ANZ J Surg. 2004 Dec;74(12):1049–1051.
   PubMed Web of Science ®Google Scholar
• Sutton PM, Cresswell T, Livesey JP, et al. Treatment of anaemia after joint replacement. A double-blind, randomised, controlled trial of ferrous sulphate versus placebo. J Bone Joint Surg Br. 2004 Jan;86(1):31–33.
   PubMedGoogle Scholar
• Crosby L, Palarski VA, Cottington E, et al. Iron supplementation for acute blood loss anemia after coronary artery bypass surgery: a randomized, placebo-controlled study. Heart Lung. 1994 Nov-Dec;23(6):493–499.
   PubMed Web of Science ®Google Scholar
• Goodnough LT, Comin-Colet J, Leal-Noval S, et al. Management of anemia in patients with congestive heart failure. Am J Hematol. 2017;92:88–93.
   PubMed Web of Science ®Google Scholar
• Lewis GD, Malhotra R, Hernandez AF, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA. 2017 May 16;317(19):1958–1966.
   PubMed Web of Science ®Google Scholar
• Shepshelovich D, Rozen-Zvi B, Avni T, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: an updated systematic review and meta-analysis. Am J Kidney Dis. 2016;68:677–690.
   PubMed Web of Science ®Google Scholar
• Muñoz M, García-Erce JA, Remacha AF. Disorders of iron metabolism. Part I: molecular basis of iron homeostasis. J Clin Pathol. 2011;64:281–286.
   PubMed Web of Science ®Google Scholar
• Santiago P. Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview. Sci World J. 2012;2012:846824.
   Web of Science ®Google Scholar
• Kaltwasser JP, Hansen C, Oebike Y, et al. Assessment of iron availability using stable 54Fe. Eur J Clin Invest. 1991;21:436–441.
   PubMed Web of Science ®Google Scholar
• Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015;126:1981–1989.
   PubMed Web of Science ®Google Scholar
• Rimon E, Kagansky N, Kagansky M, et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med. 2005;118:1142–1147.
   PubMed Web of Science ®Google Scholar
• WHO model formulary 2008 (based on WHO model list of essential medicines). [cited 2016 June 17]. Available from: http://www.who.int/selection_medicines/list/en/index.html
   Google Scholar
• Gasche C, Ahmad T, Tulassay Z, et al. Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: results from a phase-3 clinical trial program. Inflamm Bowel Dis. 2015;21:579–588.
   PubMed Web of Science ®Google Scholar
• Schmidt C, Ahmad T, Tulassay Z, et al., AEGIS Study Group. Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long-term extension data from a Phase 3 study. Aliment Pharmacol Ther. 2016 Aug; 44(3):259–270.
   PubMed Web of Science ®Google Scholar
• Mafodda A, Giuffrida D, Prestifilippo A, et al. Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoietin alpha: a phase II prospective multicenter study. Support Care Cancer. 2017;25:2779–2786. Epub ahead of print. DOI:10.1007/s00520-017-3690-z
   PubMed Web of Science ®Google Scholar
• Pisani A, Riccio E, Sabbatini M, et al. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol Dial Transplant. 2015;30:645–652.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron containing medicines. EMA/579491/2013. cited 2017 Jan 18. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/IV_iron_31/WC500151308.pdf
   Google Scholar
• Muñoz M, Breymann C, García-Erce JA, et al. Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion. Vox Sang. 2008;94:172–183.
   PubMed Web of Science ®Google Scholar
• Auerbach M, Muñoz M. Intravenous iron for treating cancer-induced anemia: meeting an unmet need? Chin Clin Oncol. 2012;1:21–23.
   PubMedGoogle Scholar
• Auerbach M, Adamson J, Bircher A, et al. On the safety of intravenous iron, evidence trumps conjecture. Haematologica. 2015;100:e214–5.
   PubMed Web of Science ®Google Scholar
• Muñoz M, Gómez-Ramírez S, Besser M, et al. Current misconceptions in diagnosis and management of iron deficiency. Blood Transfus. 2017;15:422–437.
   PubMed Web of Science ®Google Scholar
• Chertow GM, Mason PD, Vaage-Nilsen O, et al. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21(2):378–382.
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs PH, Cohen H. Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol. 2013;163(3):303–314.
   PubMed Web of Science ®Google Scholar
• Auerbach M, Macdougall I. The available intravenous iron formulations: History, efficacy, and toxicology. Hemodial Int. 2017;21(Suppl 1):S83–S89.
   Google Scholar
• Bhandari S. Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice. Ther Clin Risk Manag. 2011;7:501–509.
   PubMed Web of Science ®Google Scholar
• Wilson PD, Hutchings A, Jeans A, et al. An analysis of the health service efficiency and patient experience with two different intravenous iron preparations in a UK anaemia clinic. J Med Econ. 2013;16:108–114.
   PubMedGoogle Scholar
• Calvet X, Ruíz MÀ, Dosal A, et al. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency. PLoS One. 2012;7:e45604.
   PubMed Web of Science ®Google Scholar
• Calvet X, Gene E, Ruiz MA, et al. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia. Technol Health Care. 2016;24:111–120.
   PubMed Web of Science ®Google Scholar
• Fishbane SN, Singh AK, Cournoyer SH, et al. Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. Nephrol Dial Transplant. 2015;30:2019–2026.
   PubMed Web of Science ®Google Scholar
• Gupta A, Lin V, Guss C, et al. Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Kidney Int. 2015;88:1187–1194.
   PubMed Web of Science ®Google Scholar
• Cancelo-Hidalgo MJ, Castelo-Branco C, Palacios S, et al. Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin. 2013;29:291–303.
   PubMed Web of Science ®Google Scholar
• Tolkien Z, Stecher L, Mander AP, et al. Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis. PLoS One. 2015;10:e0117383.
   PubMed Web of Science ®Google Scholar
• Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clinic Proc. 2015;90:12–23.
   PubMed Web of Science ®Google Scholar
• Dull RB, Davis E. Heme iron polypeptide for the management of anaemia of chronic kidney disease. J Clin Pharm Ther. 2015 Aug;40(4):386–390.
   PubMed Web of Science ®Google Scholar
• Muñoz M, Martín-Montañez E. Ferric carboxymaltose for the treatment of iron-deficiency anemia. Expert Opin Pharmacother. 2012 Apr;13(6):907–921.
   PubMed Web of Science ®Google Scholar
• Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside (Monofer®) in the management of patients with iron deficiency anemia. Int J Nephrol Renovasc Dis. 2016 Mar;10(9):53–64.
   Google Scholar
• Derman R, Roman E, Modiano MR, et al. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol. 2017 Mar;92(3):286–291.
   PubMed Web of Science ®Google Scholar
• Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of ironisomaltoside 1000 versus oral iron in non-dialysis-dependentchronic kidney disease patients with anaemia. Nephrol Dial Transplant. 2016 Apr;31(4):646–655.
   PubMed Web of Science ®Google Scholar
• Rosner MH, Auerbach M. Ferumoxytol for the treatment of iron deficiency. Expert Rev Hematol. 2011 Aug;4(4):399–406.
   PubMed Web of Science ®Google Scholar
• Jahn MR, Andreasen HB, Fütterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011 Aug;78(3):480–491.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron containing medicines. EMA/579491/2013. [cited 2017 Jan 18]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/IV_iron_31/WC500151308.pdf
   Google Scholar
• Auerbach M, Macdougall IC. Safety of intravenous iron formulations: facts and folklore. Blood Transfus. 2014 Jul;12(3):296–300.
   PubMed Web of Science ®Google Scholar
• Szebeni J, Fishbane S, Hedenus M, et al. Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. Br J Pharmacol. 2015 Nov;172(21):5025–5036.
   PubMed Web of Science ®Google Scholar
• Hempel JC, Poppelaars F, Gaya da Costa M, et al. Distinct in vitro complement activation by various intravenous iron preparations. Am J Nephrol. 2017;45(1):49–59.
   PubMed Web of Science ®Google Scholar
• Wang C, Graham DJ, Kane RC, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. Jama. 2015;314:2062–2068.
   PubMed Web of Science ®Google Scholar
• Kalra PA, Bhandari S. Safety of intravenous iron use in chronic kidney disease. Curr Opin Nephrol Hypertens. 2016;25:529–535.
   PubMed Web of Science ®Google Scholar
• DeLoughery TG, Auerbach M. Is low-molecular weight iron dextran really the most risky iron? Unconvincing data from an unconvincing study. Am J Hematol. 2016;91:451–452.
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Swartz L, Borders-Hemphill BV, et al. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol. 2010;85:650–654.
   PubMed Web of Science ®Google Scholar
• Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet. 2007;369:1502–1504.
   PubMed Web of Science ®Google Scholar
• Macdougall IC, Bircher AJ, Eckardt KU, et al. Conference Participants. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016;89:28–39.
   PubMed Web of Science ®Google Scholar
• Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99(11):1671–1676.
   PubMed Web of Science ®Google Scholar
• Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science. 2012;338:768–772.
   PubMed Web of Science ®Google Scholar
• Pasricha S-R, Drakesmith H. Iron deficiency anemia. Hematol Oncol Clin America. 2016;30:309–325.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015;88:905–914.
   PubMed Web of Science ®Google Scholar
• Bhandari S, Kalra PA, Coyne DW. Data confusion. Kidney Int. 2015 Dec;88(6):1445. DOI:10.1038/ki.2015.303.
   PubMed Web of Science ®Google Scholar
• Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. Br Med J. 2013;347:f4822.
   PubMed Web of Science ®Google Scholar
• Muñoz M, Gómez-Ramírez S, Cuenca J, et al. Very-short-term perioperative intravenous iron administration and postoperative outcome in major orthopedic surgery: a pooled analysis of observational data from 2547 patients. Transfusion. 2014;54:289–299.
   PubMed Web of Science ®Google Scholar
• Torres S, Kuo YH, Morris K, et al. Intravenous iron following cardiac surgery does not increase the infection rate. Surg Infect (Larchmt). 2006 Aug;7(4):361–366.
   PubMedGoogle Scholar
• Froessler B, Palm P, Weber I, et al. The important role for intravenous iron in perioperative patient blood management in major abdominal surgery: a randomized controlled trial. Ann Surg. 2016;264:41–46.
   PubMed Web of Science ®Google Scholar
• Keeler BD, Simpson JA, Ng O, et al. Randomized clinical trial of preoperative oral versus intravenous iron in anaemic patients with colorectal cancer. Br J Surg. 2017;104:214–221. Epub ahead of print. DOI:10.1002/bjs.10328
   PubMed Web of Science ®Google Scholar
• Bisbe E, Molto L, Arroyo R, et al. Randomised trial comparing ferric carboxymaltose vs oral ferrous glycine sulphate for postoperative anaemia after total knee arthroplasty. Br J Anaesth. 2014;113:402–409.
   PubMed Web of Science ®Google Scholar
• Litton E, Baker S, Erber WN, et al.; The IRONMAN Investigators. Intravenous iron or placebo for anaemia in intensive care: the IRONMAN multicentre randomized blinded trial. A randomized trial of IV iron in critical illness. Intensive Care Med. 2016;42:1715–1722.
   PubMed Web of Science ®Google Scholar
• Khalafallah AA, Yan C, Al-Badri R, et al. Intravenous ferric carboxymaltose versus standard care in the management of postoperative anaemia: a prospective, open-label, randomized controlled trial. Lancet Haematol. 2016;3:e415–25.
   PubMed Web of Science ®Google Scholar
• Beris P, Muñoz M, García-Erce JA, et al. Perioperative anaemia management: consensus statement on the role of intravenous iron. Br J Anaesth. 2008;100:599–604.
   PubMed Web of Science ®Google Scholar
• Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017 Jul;26(4):266–275.
   PubMed Web of Science ®Google Scholar
• Rosner MH, Auerbach M. Ferumoxytol for the treatment of iron deficiency. Expert Rev Hematol. 2011;4:399–406.
   PubMed Web of Science ®Google Scholar
• Schaefer B, Würtinger P, Finkenstedt A, et al. Choice of high-dose intravenous iron preparation determines hypophosphatemia risk. PLoS ONE. 2016;11:e0167146.
   PubMed Web of Science ®Google Scholar
• Food and drug administration center for drug evaluation and research. Summary minutes of the drug safety and risk management advisory committee, February 1, 2008. [cited 2010 Jan 25]. Available from: http://www.fda.gov/ohrms/dockets/AC/08/minutes/2008-4337m1-Final.pdf.
   Google Scholar
• Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Mineral Res. 2013;28:1793–1803.
   PubMed Web of Science ®Google Scholar
• Wolf M, White KE. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens. 2014;23:411–419. Epub 2014/05/29. PubMed Central.
   PubMed Web of Science ®Google Scholar
• Bager P, Hvas CL, Dahlerup JF. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. Br J Clin Pharmacol. 2016 Nov 17. Epub ahead of print. DOI:10.1111/bcp.13189
   Web of Science ®Google Scholar
• Prats M, Font R, García C, et al. Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study. BMC Nephrol. 2013;14:167.
   PubMed Web of Science ®Google Scholar
• Hardy S, Vandemergel X. Intravenous iron administration and hypophosphatemia in clinical practice. Int J Rheumatol. 2015;2015:468675.
   PubMed Web of Science ®Google Scholar
• Bhandari S. Risk factors and metabolic mechanisms in the pathogenesis of uraemic cardiac disease. Front Biosci (Landmark Ed). 2011;16:1364–1387.
   PubMed Web of Science ®Google Scholar
• Halliwell B, Gutteridge J. Role of free radicals and catalytic metal ions in human disease: an overview. Meth Enzymol. 1990;186:1–85.
   PubMed Web of Science ®Google Scholar
• Knovich MA, Storey JA, Coffman LG, et al. Ferritin for the clinician. Blood Rev. 2009;23(3):95–104.
   PubMed Web of Science ®Google Scholar
• Aljwaid H, White DL, Collard KJ, et al. Non-transferrin-bound iron is associated with biomarkers of oxidative stress, inflammation and endothelial dysfunction in type 2 diabetes. J Diabetes Complicat. 2015;29(7):943–949.
   PubMed Web of Science ®Google Scholar
• Fell LH, Zawada AM, Rogacev KS, et al. Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant. 2014;29:809–822.
   PubMed Web of Science ®Google Scholar
• Kamanna VS, Ganji SH, Shelkovnikov S, et al. Iron sucrose promotes endothelial injury and dysfunction and monocyte adhesion/infiltration. Am J Nephrol. 2012;35:114–119.
   PubMed Web of Science ®Google Scholar
• Kuo KL, Hung SC, Wei YH, et al. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol. 2008;19(9):1817–1826.
   PubMed Web of Science ®Google Scholar
• Kuo KL, Hung SC, Lee TS, et al. Iron sucrose accelerates early atherogenesis by increasing superoxide production and up-regulating adhesion molecules in CKD. J Am Soc Nephrol. 2014;25(11):2596–2606.
   PubMed Web of Science ®Google Scholar
• Kuo K-L, Hung S-C, Lin Y-P, et al. Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS ONE. 2012;7(12):e50295.
   PubMed Web of Science ®Google Scholar
• Mimic-Oka J, Savić-Radojević A, Pljesa-Ercegovac M, et al. Evaluation of oxidative stress after repeated intravenous iron supplementation. Renal Failure. 2005;27(3):345–351.
   PubMed Web of Science ®Google Scholar
• Scheiber- Monjdehkar B, Lutzky B, Schaufler R, et al. Non–transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation. J Am Soc Nephrol. 2004;15:1648–1655.
   PubMed Web of Science ®Google Scholar
• Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol. 2004;15(6):1623–1632.
   PubMed Web of Science ®Google Scholar
• Zager RA, Johnson AC, Hanson SY, et al. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis. 2002;40(1):90–103.
   PubMed Web of Science ®Google Scholar
• Zager RA, Johnson AC, Hanson SY, et al. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int. 2004;66(1):144–156.
   PubMed Web of Science ®Google Scholar
• Shah S, Baliga R, Rajapurkar M, et al. Oxidants in chronic kidney disease. J Am Soc Nephro. 2007;18(1):16–28.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Rizkala AR, Kaskas MO, et al. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int. 2007;72(5):638–642.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Leehey DJ, Olsen SM, et al. Proteinuria induced by parenteral iron in chronic kidney disease–a comparative randomized controlled trial. Clin J Am Soc Nephrol. 2011;6(1):114–121.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015;88:905–914.
   PubMed Web of Science ®Google Scholar
• Connor JR, Zhang X, Nixon AM, et al. Comparative evaluation of nephrotoxicity and management by macrophages of intravenous pharmaceutical iron formulations. PLoS ONE. 2015;10(5):e0125272.
   PubMed Web of Science ®Google Scholar
• Martin-Malo A, Merino A, Carracedo A, et al. Effects of intravenous iron on mononuclear cells during the haemodialysis session. Nephrol Dial Transplant. 2012;27:2465–2471.
   PubMed Web of Science ®Google Scholar
• Bhandari S. Iron therapy in patients with chronic kidney disease. Transfus Alternatives Transfus Med. 2012;1–7. DOI:10.1111/j.1778-428X.2012.01156.x
   Google Scholar
• Ponikowski P, Filippatos G, Colet JC, et al. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Eur J Heart Fail. 2014;17(3):329–339.
   Web of Science ®Google Scholar
• Drüeke T, Witko-Sarsat V, Massy Z, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002;106:2212–2217.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2014;36(11):657–668.
   PubMed Web of Science ®Google Scholar
• Taylor D, Bhandari S, Seymour AM. Mitochondrial dysfunction in uremic cardiomyopathy. Am J Physiol Renal Physiol. 2015;308(6):F579–587.
   PubMed Web of Science ®Google Scholar
• Nuhu F, Seymour AM, Sturmey R, et al. Iron therapy modifies oxidative stress in uraemic cardiomyopathy  [TH-PO486]. J Am Soc Nephrol 2017;28 (Abstract edition):225.
   Google Scholar
• Bailie GR. Comparison of rates of reported adverse events associated with i.v. iron products in the United States. Am J Health Syst Pharm. 2012;69:310–320.
   PubMed Web of Science ®Google Scholar
• Bailie GR, Larkina M, Goodkin DA, et al. Data from the dialysis outcomes and practice patterns study validate an association between high intravenous iron doses and mortality. Kidney Int. 2015 Jan;87(1):162–168.
   PubMed Web of Science ®Google Scholar
• Carson JL, Stanworth SJ, Roubinian N, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2016;10:CD002042.
   PubMed Web of Science ®Google Scholar
• Weiss G. Anemia of chronic disorders: new diagnostic tools and new treatment strategies. Semin Hematol. 2015;52:313–320.
   PubMed Web of Science ®Google Scholar
• Besarab A, Chernyavskaya E, Motylev I, et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J Am Soc Nephrol. 2016;27:1225–1233.
   PubMed Web of Science ®Google Scholar
• Grabner A, Amaral AP, Schramm K, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 2015 Dec 1;22(6):1020–1023.
   PubMed Web of Science ®Google Scholar